Our aim is to uncover the mechanisms underlying cognitive and social alterations relevant to psychiatric and neurodevelopmental disorders with the final goal of developing biologically-based and personalized therapeutic strategies. We employ cross-disciplinary approaches including detailed in vivo studies in genetically modified mice strictly combined with clinical investigations.

• To implement more efficient and biologically-supported personalized medicine for cognitive and social alterations relevant to psychiatric and neurodevelopmental disorders.
• To develop a bidirectional mouse-human approach to accelerate the development of precision medicine strategies, with a deeper understanding of the biological mechanisms involved.
• To investigate genetics, circuits, and cell-type specific mechanisms underlying higher-order cognitive and social processes.
• To understand the brain-immune system interplay in modulating cognitive and social functions, their developmental trajectories, and the impact of early treatments.

• HIGHER-ORDER COGNITIVE PROCESSES
• SOCIAL COGNITION
• GENETICS
• IMMUNE BRAIN COMMUNICATION

• February 2020-February 2023: Principal Investigator. Fondazione Telethon – project GGP19103, title: “Improving developmental trajectories in 22q11.2 deletion syndrome by oxytocin: focus on anti-inflammatory effects”. 
• September 2019-September 2022: Co-PI, work package leader. AIFA (Agenzia Italiana del Farmaco). Title: “Cannabidiol as an add-on treatment to substance abuse in juvenile patients with psychosis: a double-blind randomized placebo-controlled study (CAT-PSY)”. 
• November 2018-November 2021: Principal Investigator. Ricerca Finalizzata Giovani Ricercatori 2016 - Ministero Salute – project GR-2016-02362413, title: “Dysbindin-antipsychotics psychophamarcogenetics: a mouse-human translational study towards personalized healthcare in bipolar disorders”. 
• September 2018-September 2020: Supervisor and hosting lab. Marie Sklodowska-Curie individual Fellowships European to Celine Devroye. SOCIALBRAINCIRCUITS. 
• July 2018- August 2020: Principal Investigator. Boehringer Ingelheim Pharma. Title: “Role of the frontocortical-parvalbumin system in higher-order cognitive functions and in the onset of cognitive deficits induced by schizophrenia-relevant mutations”.
• October 2018: Principal Investigator. The MINDDS Action of the European COST Association (eCOST). Training school/hands-on workshop in “Convergence Neuroscience: bridging the gap between human patients and animal models of neurodevelopmental disorders”. 
• March 2016- December 2018: Principal Investigator. Compagnia di San Paolo grant n. 2015-0321. Title: “Utilizzo di variazioni genetiche in dysbindin-1 (dtnbp1) per lo sviluppo di trattamenti più efficaci e personalizzati per la schizofrenia”.
• September 2015-March 2018: Principal Investigator. Brain & Behavior Research Foundation, 2015 NARSAD Independent Investigator grant n. 23234; Title: “Use of genetic-driven dysbindin-1 (DTNBP1) variations for more effective and personalized treatments in First Episode of Psychosis”.
• January 2013-January 2017: Principal Investigator. Roche Postdoc Fellowship Program; title: “D2L/S-dysbindin genetic interaction: towards early detection and personalized interventions for cognitive deficits and schizophrenia”. 

More grants have been won by our PI, before the official line kick off 

• January 2014-December 2015: in charge of a work package. 2013 NARSAD Young Investigator grant. Title: “Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11 microdeletion syndrome genetically at high risk for psychosis: A randomised, double blind, placebo-controlled treatment trial”.
• January 2013-May 2016: Principal Investigator. Ricerca Finalizzata Giovani Ricercatori 2010 - Ministero Salute – project GR-2010-2315883, title: “Schizophrenia pathogenetic mechanisms associated to dysbindin dysfunctions in fly and mouse models”.
• September 2010-September 2014: Principal Investigator. Marie Curie FP7-Reintegration-Grants Call identifier: FP7-PEOPLE-2010-RG Grant N° 268247 – "SCHIZOGENES".
• August 2008-August 2010: Principal Investigator. NIMH Julius Axelrod Memorial Fellowship Training Award. Behavioral characterization of genetically modified mice for schizophrenia-associated susceptibility genes.

Within IIT

• Alessandro Gozzi: structural and functional MRI in mouse models
• Ferruccio Pisanello: optogenetics and fiberphotometry probes for in vivo manipulations
• Laura Cancedda: electrophysiology and neurodevelopmental disorders
• Paolo Decuzzi: new drug delivery systems targeting the brain
• Pier Paolo Pompa: colorimetric kit for genetic tests in humans
• Roberto Marotta: electron microscopy analyses
• Stefano Gustincich: SINEUPs for the OXTergic system and for the 22q11.2DS
• Vittorio Murino & Diego Sona: software development and pattern analyses of complex behaviors

External

• Gunter Schumann (Fudan University, China): human fMRI, clinical data and samples.
• Alexandre Charlet (University of Strasburg, France): astrocytes.
• Stefano Panzeri (University of Hamburg-Eppendorf, Germany): data analyses and modeling.
• Inbal Goshen (Hebrew University, Israel): astrocytes.
• Stefano Vicari (Bambino Gesu’ Hospital): clinical data and samples.
• Paolo Brambilla (Policlinico Milano): human MRI, clinical data and samples.
• Stephan Eliez (University of Geneve, Switzerland): human MRI, clinical data and samples.
• Daniel Weinberger (Lieber Institute, USA): post mortem human brains and human genetic data.
• Ofer Yizhar (Weizmann Institute, Israel): optogenetics.
• Giovanni Marsicano (INSERM, France): cannabinoid system.
• Valery Grinevich (Heidelberg University, Germany): oxytocin system.
• Davide Ragozzino (Sapienza, Roma): microglia.
• Bice Chini (CNR, Milano): oxytocin system.
• Fabio Fumagalli (University of Milano): cellular mechanisms.
• Angelo Contarino (University of Bordeaux, France): CRF system.
• Filippo Drago, Gian Marco Leggio (University of Catania): genetically modified mouse models.
• Sara De Martin (University of Padova): immune system.
• Mary De Luca (University of Cagliari): dopamine microdialysis.